非酒精性脂肪性肝炎是美国肝移植增长最快的适应证
基于美国移植受者科学登记系统2002至2019年数据,分析168441例已知病因的成人肝移植等待者病因构成趋势。2019年无肝细胞癌患者中非酒精性脂肪性肝炎为第二常见适应证(28%),仅次于酒精相关肝病(38%),且为增长最快的适应证(Kendall tau=0.97;P < .001)。
要点
- 2019年无肝细胞癌患者中非酒精性脂肪性肝炎占28%,为第二常见肝移植适应证。
- 2019年有肝细胞癌患者中非酒精性脂肪性肝炎占24%,超过酒精相关肝病(16%)居第二。
- 非酒精性脂肪性肝炎是增长最快的肝移植适应证(无肝细胞癌 Kendall tau=0.97;P < .001)。
核心结论
- 2019年非酒精性脂肪性肝炎为肝移植第二常见适应证,且为增长最快的适应证。
- 2019年无肝细胞癌女性中非酒精性脂肪性肝炎为肝移植首位适应证。
研究设计与样本
- 研究为基于美国移植受者科学登记系统(2002至2019年)的数据分析。
- 纳入168441例已知病因且非急性肝衰竭的成人肝移植等待者,其中27799例(16.5%)有肝细胞癌。
主要发现
- 2002年无肝细胞癌患者中,慢性丙型肝炎感染占37%、酒精相关肝病占16%、非酒精性脂肪性肝炎占5%。
- 2002年有肝细胞癌患者中,慢性丙型肝炎感染占58%、酒精相关肝病占10%、非酒精性脂肪性肝炎占1%。
- 2019年无肝细胞癌患者中,酒精相关肝病占38%、非酒精性脂肪性肝炎占28%,非酒精性脂肪性肝炎居第二。
- 2019年有肝细胞癌患者中,慢性丙型肝炎感染占40%、非酒精性脂肪性肝炎占24%、酒精相关肝病占16%,非酒精性脂肪性肝炎超过酒精相关肝病居第二。
- 趋势分析中,非酒精性脂肪性肝炎在无肝细胞癌患者(Kendall tau=0.97;P < .001)和有肝细胞癌患者(tau=0.94;P < .0001)中均为增长最快的肝移植适应证。
关键数值与推荐
- 无肝细胞癌女性中非酒精性脂肪性肝炎占34%,为肝移植首位适应证。
- 54岁以上患者中非酒精性脂肪性肝炎占36%,为肝移植首位适应证。
- 联邦医疗保险(Medicare)患者中非酒精性脂肪性肝炎占41%,为肝移植首位适应证。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The profile of chronic liver disease (CLD) in the United States has changed due to obesity trends and advances in treatment of viral hepatitis. We assessed liver transplant listing trends by CLD etiology. METHODS: Adult candidates for liver transplantation were selected from the Scientific Registry of Transplant Recipients (2002 through 2019). We calculated proportion trends for common CLD etiologies at time of placement on the wait list, including chronic infection with hepatitis B virus, chronic infection with hepatitis C virus (HCV), nonalcoholic steatohepatitis (NASH, including cryptogenic cirrhosis), alcohol-related liver disease (ALD) without or with chronic HCV infection, autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis, in patients with and without hepatocellular carcinoma (HCC). RESULTS: From the 168,441 patients with known etiology and non-acute liver failure on the liver transplant waitlist, 27,799 patients (16.5%) had HCC. In 2002, the most common etiologies in patients without HCC were chronic HCV infection (37%) and ALD (16%), whereas only 5% had NASH. Among patients with HCC, 58% had chronic HCV infection and 10% had ALD and only 1% had NASH. In 2019, among patients without HCC, NASH was the second leading indication for liver transplantation (28% of patients), after ALD (38% of patients). Among patients with HCC, chronic HCV infection remained the leading indication (40% of patients) but NASH (24% of patients) surpassed ALD (16% of patients) to become the second leading indication. NASH was the leading indication in women without HCC (34%), in patients older than 54 years (36%), and in patients on Medicare (41%). In trend analysis, NASH was the most rapidly increasing indication for liver transplantation in patients without HCC (Kendall tau=0.97; P < .001) and in patients with HCC (tau=0.94; P < .0001). CONCLUSIONS: In an analysis of data from the Scientific Registry of Transplant Recipients (2002 through 2019), we found NASH to be the second most common indication for liver transplant in 2019, and the fastest increasing indication. In 2019, NASH was the leading indication for liver transplantation among women without HCC.
引用
- Younossi ZM, Stepanova M, Ong J, et al. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol. 2020. PMID: 32531342. doi:10.1016/j.cgh.2020.05.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。